Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD

The oral multi-target kinase inhibitor regorafenib, which targets the oncogenic receptor tyrosine kinase (RTK), is an effective therapeutic for patients with advanced gastrointestinal stromal tumors or metastatic colorectal cancer. However, whether regorafenib treatment has beneficial effects on neu...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kyung-Min, Kang, Ri Jin, Jeon, Hyongjun, Lee, Hyun-ju, Lee, Ji-Soo, Park, HyunHee, Gak Jeon, Seong, Suk, Kyoungho, Seo, Jinsoo, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408082/
https://www.ncbi.nlm.nih.gov/pubmed/32660121
http://dx.doi.org/10.3390/cells9071655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408082/
https://www.ncbi.nlm.nih.gov/pubmed/32660121
http://dx.doi.org/10.3390/cells9071655

Ejemplares similares